← Drug-vs-drug verdicts

CagriSema vs Zepbound (2026): Investigational Amylin+GLP-1 vs Approved GIP+GLP-1

CagriSema (cagrilintide + semaglutide, Novo Nordisk) vs Zepbound (tirzepatide, Eli Lilly)

Last verified 2026-07-06

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed

The verdict

CagriSema and Zepbound stand at the frontier of pharmacological weight loss, and their phase 3 efficacy data are strikingly close: REDEFINE-1 showed ~20.4% mean body-weight reduction with CagriSema at 68 weeks (PMID 40544433), while SURMOUNT-1 showed up to ~20.9% with tirzepatide 15 mg at 72 weeks (PMID 35658024). These are cross-trial comparisons with different study populations and designs, and no head-to-head RCT comparing CagriSema to tirzepatide exists as of mid-2026, making a definitive efficacy verdict impossible. They also work through different dual mechanisms — CagriSema pairs an amylin receptor agonist (cagrilintide) with a GLP-1 receptor agonist (semaglutide), while Zepbound co-activates both GIP and GLP-1 receptors with tirzepatide. The decisive practical difference is approval status: Zepbound is FDA-approved since November 2023 and commercially available, while CagriSema remains investigational with no confirmed regulatory submission date as of mid-2026. For patients seeking the most effective currently-approved treatment, Zepbound is the answer; CagriSema may become a second high-efficacy option once approved, potentially serving patients who plateau on GIP/GLP-1 dual agonism.

Side-by-side comparison

FieldCagriSemaZepbound
Peak weight loss (vs placebo)~20.4% at 68 wk — REDEFINE-1 (PMID 40544433)Up to ~20.9% (15 mg arm) at 72 wk — SURMOUNT-1 (PMID 35658024)
Head-to-head dataNo direct RCT vs tirzepatide reported as of mid-2026No direct RCT vs CagriSema reported as of mid-2026
Mechanism of actionAmylin receptor + GLP-1 receptor agonist (cagrilintide + semaglutide 2.4 mg)Dual GIP receptor + GLP-1 receptor agonist (tirzepatide)
FDA approval statusInvestigational — not FDA-approved (as of mid-2026)FDA-approved for chronic weight management since November 2023
Cardiovascular outcomesNo completed CV outcomes trial; data pendingSURMOUNT-MMO trial ongoing; CV indication not yet approved
AdministrationOnce-weekly subcutaneous injection (investigational dosing)Once-weekly subcutaneous injection (2.5–15 mg, dose escalation)
Commercial availability & priceNot commercially available — clinical trials onlyAvailable by prescription; ~$550/mo with Lilly savings card

Frequently asked questions

Is CagriSema better than Zepbound for weight loss?

Phase 3 data show nearly identical efficacy: CagriSema ~20.4% (REDEFINE-1) vs Zepbound up to ~20.9% at the 15 mg dose (SURMOUNT-1). These are cross-trial comparisons with different populations — no direct head-to-head RCT exists as of mid-2026. The difference is within the margin of cross-trial uncertainty and cannot be used to declare either superior.

Which drug has a better mechanism — CagriSema or Zepbound?

They use distinct dual-receptor strategies. CagriSema activates amylin and GLP-1 receptors using two separate molecules; Zepbound activates GIP and GLP-1 receptors using a single molecule (tirzepatide). Both approaches outperform GLP-1 monotherapy; neither has been proven superior to the other in a head-to-head trial.

When will CagriSema be approved compared to Zepbound?

Zepbound received FDA approval in November 2023. CagriSema is investigational with no confirmed NDA submission date as of mid-2026. If Novo Nordisk files in 2026, FDA review would typically take 6–12 months.

Could CagriSema help patients who stopped responding to Zepbound?

Possibly. Because CagriSema works through amylin receptor agonism rather than GIP receptor agonism, its mechanism is distinct from Zepbound's. A patient who has plateaued on Zepbound might respond differently to CagriSema's complementary pathway — but no clinical data on sequential use currently exist.

Do CagriSema and Zepbound have the same side effects?

Both produce GLP-1-class gastrointestinal side effects (nausea, vomiting, diarrhea, constipation). Zepbound's added GIP component and CagriSema's added amylin component each modulate satiety through different secondary pathways, so their tolerability profiles may differ in subtle ways — but no head-to-head comparison data are available.

What is the price difference between CagriSema and Zepbound?

CagriSema has no commercial price — it is not yet approved or sold. Zepbound (tirzepatide) costs approximately $550/mo with Eli Lilly's savings card for eligible patients without insurance. List price is higher.

References

  1. 1.Garvey WT, Blüher M, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) N Engl J Med. 2025;393(7):635-647. 2025. PMID: 40544433.
  2. 2.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) N Engl J Med. 2022;387(3):205-216. 2022. PMID: 35658024.
  3. 3.Davies MJ, Bajaj HS, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2) N Engl J Med. 2025;393(7):648-659. 2025. PMID: 40544432.
  4. 4.Yamauchi T, Becker NP, Hagemann CA, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity Lancet Diabetes Endocrinol. 2026;14(6):450-462. 2026. PMID: 42009015.
  5. 5.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) N Engl J Med. 2021;384(11):989-1002. 2021. PMID: 33567185.

Related comparisons

See the full drug-vs-drug verdict index or provider rankings.